47 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
13 Aug 24
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
8:01am
for the three months ended June 30, 2024, and 2023, respectively.
R&D Expense: Research and development expenses for the second quarter of 2024 were $15.4
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
31, 2024 and 2023, respectively.
R&D Expense: Research and development expenses for the first quarter of 2024 were $15.5 million, including non-cash
8-K
EX-99.1
x1w5p5udsp eg9
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
CORRESP
9p9bd xln
27 Nov 23
Correspondence with SEC
12:00am
8-K
EX-99.1
0kkwgt
14 Nov 23
UroGen Pharma Reports Third Quarter 2023 Financial Results
12:00am
8-K
EX-99.1
qqtho7l mkmwl6zlswg8
10 Aug 23
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
8:01am
8-K
EX-99.1
2hehukmypqvc
11 May 23
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
8:05am
8-K
EX-99.1
k2swexrld5
10 Nov 22
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:10am
8-K
EX-99.1
x1ivhspxc 851x1
11 Aug 22
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
8:11am
8-K
EX-99.1
x8k1fqhy9clgdoq
10 May 22
UroGen Pharma Reports First Quarter 2022 Financial Results
9:11am